Sarpogrelate
Small molecule targets HTR2A via inhibition
Trials 20
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 18 trials | ||||||
| Phase 1 | NCT03947489 | Mar → May 2019 | — | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 1 | NCT03947528 | Mar → May 2019 | — | Daewoong Pharmaceutical Co. LTD. | Unknown | No outcome recorded |
| Phase 1 | NCT03573622 | May → Aug 2018 | — | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 1 | NCT03574285 | May → Aug 2018 | — | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 1 | NCT02097511 | Dec 2013 → Jan 2014 | hypertensive disorder, peripheral arterial disease | Ajou University School of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT01841086 | Sep → Nov 2011 | — | Korea United Pharm. Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01429688 | Jul → Aug 2011 | — | Alvogen Korea | Completed | No outcome recorded |
| Phase 1 | NCT01421563 | Feb 2011 | — | Alvogen Korea | Completed | No outcome recorded |
| Phase 33 trials · 1 missed | ||||||
| Phase 3 | NCT02393612 | Oct 2012 → Apr 2014 | peripheral arterial disease | Alvogen Korea | Completed | No outcome recorded |
| Phase 3 | NCT00147303 | Apr 2004 → Jan 2005 | cerebral infarction | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00129805 | Jan 2001 → Sep 2004 | cerebral infarction | Tanabe Pharma Corporation | Completed | Missed primary |
| Phase 47 trials · 1 met primary · 1 missed | ||||||
| Phase 4 | NCT05730621 | Jan 2023 → Feb 2024 | coronary artery disorder, peripheral arterial disease | Yuhan Corporation | Completed | No outcome recorded |
| Phase 4 | NCT06046196 | Nov 2020 → Mar 2023 | arterial occlusion, intermittent vascular claudication | Yuhan Corporation | Completed | No outcome recorded |
| Phase 4 | NCT03509922 | Oct 2018 → Dec 2019 | peripheral arterial disease | Yuhan Corporation | Completed | No outcome recorded |
| Phase 4 | NCT02959606 | Dec 2016 → Jan 2019 | peripheral arterial disease | Seoul National University Hospital | Unknown | Met primary |
| Phase 4 | NCT02607436 | Jul 2015 → Feb 2016 | coronary artery disorder | Seoul National University Bundang Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01674686 | Aug 2012 → Dec 2018 | Prinzmetal angina | Samsung Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT01165567 | Dec 2009 → Dec 2010 | chronic kidney disease | Seoul National University Boramae Hospital | Unknown | Missed primary |
| Phase not applicable2 trials | ||||||
| — | NCT06424548 | May 2024 → Jun 2028 expected | atherosclerosis, ischemic stroke | Ewha Womans University Seoul Hospital | Not yet recruiting | No outcome recorded |
| — | NCT01548274 | Oct 2010 → Oct 2012 | atherosclerosis | Aichi Gakuin University | Unknown | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT02294643 Comparator | Apr 2009 → Mar 2012 | chronic kidney disease, coronary artery disorder, diabetes mellitus | Seoul National University Bundang Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01869881 Comparator | Feb 2013 → Nov 2014 | diabetic kidney disease | Yuhan Corporation | Completed | No outcome recorded |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 23 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sarpogrelate | “To evaluate the bioequivalence of two formulations of Sarpogrelate HCl 300mg, Anpl-one SR Tab. 300mg (Reference) and generic Sarpogrelate HCl 300mg (Test), after a single oral...” NCT03573622 ↗19“Effect of sarpogrelate, a 5-HT(2A) antagonist, on platelet aggregation in patients with ischemic stroke: clinical-pharmacological dose-response study.” PMID 17622759 ↗ Jul 2007 “DP-R202 (Sarpogrelate HCl 300mg, qd) with those of Anplag (Sarpogrelate HCl 100mg, tid) after oral administration in healthy male volunteers.” NCT01421563 ↗ “Sarpogrelate hydrochloride, a selective 5-HT2A antagonist, has been widely used as an anti-platelet agent for the treatment of PAD.” NCT02393612 ↗ “A Single-dose, Comparative Bioavailability Study of Two Formulations of Sarpogrelate HCl 300mg Tablets Under Feeding Conditions” NCT03574285 ↗ “Sarpogrelate HCl 300mg once a day or 100mg three times a day for 3 days” NCT01429688 ↗ “sarpogrelate hydrochloride 100mg bid for 24 weeks” NCT03509922 ↗ |
| Known as | Anpl-one SR Tab. | “To evaluate the bioequivalence of two formulations of Sarpogrelate HCl 300mg, Anpl-one SR Tab. 300mg (Reference) and generic Sarpogrelate HCl 300mg (Test), after a single oral...” NCT03573622 ↗ |
| Known as | Anplag | “The purpose of this study is compare the safety and pharmacokinetic characteristics of DP-R202 (Sarpogrelate HCl 100mg, qd) with those of Anplag (Sarpogrelate HCl 100mg, tid)...” NCT01429688 ↗ |
| Known as | DP-R202 | “The purpose of this study is compare the safety and pharmacokinetic characteristics of DP-R202 (Sarpogrelate HCl 100mg, qd) with those of Anplag (Sarpogrelate HCl 100mg, tid)...” NCT01429688 ↗1“Patients administrate DP-R202 (Sarpogrelate 300mg) once a day for 12 weeks” NCT02393612 ↗ |
| Known as | LS-187118 | ChEMBL registry synonym — accepted as the source's own label CHEMBL52939 ↗ |
| Known as | MCI-9042 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00129805 ↗ |
| Known as | Sarpogrelate HCl | “The purpose of this study is compare the safety and pharmacokinetic characteristics of DP-R202 (Sarpogrelate HCl 100mg, qd) with those of Anplag (Sarpogrelate HCl 100mg, tid)...” NCT01429688 ↗2“DP-R202 (Sarpogrelate HCl 300mg, qd) with those of Anplag (Sarpogrelate HCl 100mg, tid) after oral administration in healthy male volunteers.” NCT01421563 ↗ “Sarpogrelate HCL 300mg” NCT03947489 ↗ |
| Known as | Sarpogrelate hydrochloride | “Sarpogrelate hydrochloride, a selective 5-HT2A antagonist, has been widely used as an anti-platelet agent for the treatment of PAD.” NCT02393612 ↗1“Anplone SR®, controlled-released Sarpogrelate hydrochloride, has been introduced as an anti-platelet agent for the drug of PAD.” NCT02959606 ↗ |
| Known as | SARPOGRELATE HYROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL52939 ↗ |
| Known as | Sarpogrelato | ChEMBL registry synonym — accepted as the source's own label CHEMBL52939 ↗ |
| Action | Inhibit | “a selective 5-hydroxytryptamine (5-HT(2A)) receptor antagonist” PMID 17622759 ↗ Jul 20071“Serotonin 2a (5-HT2a) receptor antagonist” CHEMBL52939 ↗ |
| Modality | Small molecule | — CHEMBL52939 ↗ |
| Route | Oral | “15 patients received 25 mg sarpogrelate (group L), 16 patients received 50 mg (group M), and 15 patients received 100 mg (group H) orally, three times daily for 7 days” PMID 17622759 ↗ Jul 2007 |
| Target | HTR2A | “Serotonin 2a (5-HT2a) receptor antagonist” CHEMBL52939 ↗ |